TZT-1027 elucidates antitumor activity through direct cytotoxicity and selective blockade of blood supply

Naoko Hashiguchi, Tetsuro Kubota, Jun Ichi Koh, Yoshinori Yamada, Yoshiro Saikawa, Yoshihide Otani, Masahiko Watanabe, Koichiro Kumai, Masaki Kitajima, Jun Ichi Watanabe, Motohiro Kobayashi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: TZT-1027 is a newly developed antitumor agent derived from dolastatin 10. Materials and Methods: The in vitro activity of TZT-1027 on MCF-7 and R-27 cells was evaluated by MTT assay. TZT-10271 mg/kg/week was administered i.v. for 4 weeks into nude mice bearing MCF-7 and R-27. Subsequently, primary cultured cells from xenografts were also used for CD-DST. Two mg of TZT-1027 or 40 mg docetaxel per kg were injected i.v. into nude mice bearing R-27. 0.2% Evans blue was injected to assess the blood flow. Results: TZT-1027 suppressed the in vitro growth of MCF-7 cells, while R-27 cells were resistant to TZT-1027, although its in vivo antitumor activity was remarkable. TZT-1027 blockaded R-27 tumor blood flow immediately after injection; blood flow was not affected by docetaxel. Conclusion: TZT-1027 exerts its antitumor activity through direct cytotoxicity against MCF-7 cells and through selective blockade of tumor blood flow against R-27 cells.

Original languageEnglish
Pages (from-to)2201-2208
Number of pages8
JournalAnticancer Research
Volume24
Issue number4
Publication statusPublished - 2004 Jul

Fingerprint

docetaxel
dolastatin 10
MCF-7 Cells
Nude Mice
Evans Blue
soblidotin
Heterografts
Antineoplastic Agents
Cultured Cells
Neoplasms
Injections
Growth
In Vitro Techniques

Keywords

  • Breast cancer
  • Nude mouse
  • TZT-1027
  • Vascular flow

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hashiguchi, N., Kubota, T., Koh, J. I., Yamada, Y., Saikawa, Y., Otani, Y., ... Kobayashi, M. (2004). TZT-1027 elucidates antitumor activity through direct cytotoxicity and selective blockade of blood supply. Anticancer Research, 24(4), 2201-2208.

TZT-1027 elucidates antitumor activity through direct cytotoxicity and selective blockade of blood supply. / Hashiguchi, Naoko; Kubota, Tetsuro; Koh, Jun Ichi; Yamada, Yoshinori; Saikawa, Yoshiro; Otani, Yoshihide; Watanabe, Masahiko; Kumai, Koichiro; Kitajima, Masaki; Watanabe, Jun Ichi; Kobayashi, Motohiro.

In: Anticancer Research, Vol. 24, No. 4, 07.2004, p. 2201-2208.

Research output: Contribution to journalArticle

Hashiguchi, N, Kubota, T, Koh, JI, Yamada, Y, Saikawa, Y, Otani, Y, Watanabe, M, Kumai, K, Kitajima, M, Watanabe, JI & Kobayashi, M 2004, 'TZT-1027 elucidates antitumor activity through direct cytotoxicity and selective blockade of blood supply', Anticancer Research, vol. 24, no. 4, pp. 2201-2208.
Hashiguchi N, Kubota T, Koh JI, Yamada Y, Saikawa Y, Otani Y et al. TZT-1027 elucidates antitumor activity through direct cytotoxicity and selective blockade of blood supply. Anticancer Research. 2004 Jul;24(4):2201-2208.
Hashiguchi, Naoko ; Kubota, Tetsuro ; Koh, Jun Ichi ; Yamada, Yoshinori ; Saikawa, Yoshiro ; Otani, Yoshihide ; Watanabe, Masahiko ; Kumai, Koichiro ; Kitajima, Masaki ; Watanabe, Jun Ichi ; Kobayashi, Motohiro. / TZT-1027 elucidates antitumor activity through direct cytotoxicity and selective blockade of blood supply. In: Anticancer Research. 2004 ; Vol. 24, No. 4. pp. 2201-2208.
@article{115046eb50a14428a39acdd4d04ed4c0,
title = "TZT-1027 elucidates antitumor activity through direct cytotoxicity and selective blockade of blood supply",
abstract = "Background: TZT-1027 is a newly developed antitumor agent derived from dolastatin 10. Materials and Methods: The in vitro activity of TZT-1027 on MCF-7 and R-27 cells was evaluated by MTT assay. TZT-10271 mg/kg/week was administered i.v. for 4 weeks into nude mice bearing MCF-7 and R-27. Subsequently, primary cultured cells from xenografts were also used for CD-DST. Two mg of TZT-1027 or 40 mg docetaxel per kg were injected i.v. into nude mice bearing R-27. 0.2{\%} Evans blue was injected to assess the blood flow. Results: TZT-1027 suppressed the in vitro growth of MCF-7 cells, while R-27 cells were resistant to TZT-1027, although its in vivo antitumor activity was remarkable. TZT-1027 blockaded R-27 tumor blood flow immediately after injection; blood flow was not affected by docetaxel. Conclusion: TZT-1027 exerts its antitumor activity through direct cytotoxicity against MCF-7 cells and through selective blockade of tumor blood flow against R-27 cells.",
keywords = "Breast cancer, Nude mouse, TZT-1027, Vascular flow",
author = "Naoko Hashiguchi and Tetsuro Kubota and Koh, {Jun Ichi} and Yoshinori Yamada and Yoshiro Saikawa and Yoshihide Otani and Masahiko Watanabe and Koichiro Kumai and Masaki Kitajima and Watanabe, {Jun Ichi} and Motohiro Kobayashi",
year = "2004",
month = "7",
language = "English",
volume = "24",
pages = "2201--2208",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - TZT-1027 elucidates antitumor activity through direct cytotoxicity and selective blockade of blood supply

AU - Hashiguchi, Naoko

AU - Kubota, Tetsuro

AU - Koh, Jun Ichi

AU - Yamada, Yoshinori

AU - Saikawa, Yoshiro

AU - Otani, Yoshihide

AU - Watanabe, Masahiko

AU - Kumai, Koichiro

AU - Kitajima, Masaki

AU - Watanabe, Jun Ichi

AU - Kobayashi, Motohiro

PY - 2004/7

Y1 - 2004/7

N2 - Background: TZT-1027 is a newly developed antitumor agent derived from dolastatin 10. Materials and Methods: The in vitro activity of TZT-1027 on MCF-7 and R-27 cells was evaluated by MTT assay. TZT-10271 mg/kg/week was administered i.v. for 4 weeks into nude mice bearing MCF-7 and R-27. Subsequently, primary cultured cells from xenografts were also used for CD-DST. Two mg of TZT-1027 or 40 mg docetaxel per kg were injected i.v. into nude mice bearing R-27. 0.2% Evans blue was injected to assess the blood flow. Results: TZT-1027 suppressed the in vitro growth of MCF-7 cells, while R-27 cells were resistant to TZT-1027, although its in vivo antitumor activity was remarkable. TZT-1027 blockaded R-27 tumor blood flow immediately after injection; blood flow was not affected by docetaxel. Conclusion: TZT-1027 exerts its antitumor activity through direct cytotoxicity against MCF-7 cells and through selective blockade of tumor blood flow against R-27 cells.

AB - Background: TZT-1027 is a newly developed antitumor agent derived from dolastatin 10. Materials and Methods: The in vitro activity of TZT-1027 on MCF-7 and R-27 cells was evaluated by MTT assay. TZT-10271 mg/kg/week was administered i.v. for 4 weeks into nude mice bearing MCF-7 and R-27. Subsequently, primary cultured cells from xenografts were also used for CD-DST. Two mg of TZT-1027 or 40 mg docetaxel per kg were injected i.v. into nude mice bearing R-27. 0.2% Evans blue was injected to assess the blood flow. Results: TZT-1027 suppressed the in vitro growth of MCF-7 cells, while R-27 cells were resistant to TZT-1027, although its in vivo antitumor activity was remarkable. TZT-1027 blockaded R-27 tumor blood flow immediately after injection; blood flow was not affected by docetaxel. Conclusion: TZT-1027 exerts its antitumor activity through direct cytotoxicity against MCF-7 cells and through selective blockade of tumor blood flow against R-27 cells.

KW - Breast cancer

KW - Nude mouse

KW - TZT-1027

KW - Vascular flow

UR - http://www.scopus.com/inward/record.url?scp=4444305445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444305445&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 2201

EP - 2208

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -